Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Ampicillin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 10/20 | 1.00 |
| ▸ | RECQL | P46063 | 4/20 | 1.00 |
| ▸ | HPGD | P15428 | 4/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 1.00 |
| ▸ | POLB | P06746 | 2/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 1/20 | 1.00 |
| ▸ | TEK | Q02763 | 1/20 | 1.00 |
| ▸ | SLC15A2 | Q16348 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 6/20 | 0.98 |
| ▸ | TSHR | P16473 | 2/20 | 0.98 |
| ▸ | RARB | P10826 | 1/20 | 0.84 |
| ▸ | RARG | P13631 | 1/20 | 0.84 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.84 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.84 |
| ▸ | NR1I3 | Q14994 | 1/20 | 0.84 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.82 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.82 |
| ▸ | GLA | P06280 | 1/20 | 0.82 |
| ▸ | BLM | P54132 | 1/20 | 0.82 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ampicillin SCHEMBL11985596 | 1.00 | KDM4E (1.00) | KDM4ERECQLHPGDTDP1POLB | |
| Ampicillin SCHEMBL13240124 | 1.00 | KDM4E (1.00) | KDM4ERECQLHPGDTDP1POLB | |
| Ampicillin SCHEMBL3467975 | 1.00 | KDM4E (1.00) | KDM4ERECQLHPGDTDP1POLB | |
| Ampicillin SCHEMBL3526 | 1.00 | KDM4E (1.00) | KDM4ERECQLHPGDTDP1POLB | |
| Ampicillin SCHEMBL13007617 | 1.00 | KDM4E (1.00) | KDM4ERECQLHPGDTDP1POLB | |
| Ampicillin SCHEMBL24312533 | 1.00 | KDM4E (1.00) | KDM4ERECQLHPGDTDP1POLB | |
| Ampicillin SCHEMBL9528765 | 1.00 | KDM4E (1.00) | KDM4ERECQLHPGDTDP1POLB | |
| Ampicillin SCHEMBL11384703 | 1.00 | KDM4E (1.00) | KDM4ERECQLHPGDTDP1POLB | |
| Ampicillin SCHEMBL22380861 | 1.00 | KDM4E (1.00) | KDM4ERECQLHPGDTDP1POLB | |
| Ampicillin SCHEMBL13014516 | 1.00 | KDM4E (1.00) | KDM4ERECQLHPGDTDP1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 128 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4740959-A2 | THERAPEUTIC USE OF LEVOROTATORY -LACTAMS IN HEMATOPOIESIS, IMMUNO-ONCOLOGY THERAPY, AND REGULATION OF LIPOPROTEIN AND APOLIPOPROTEIN LEVELS | Alpha-1 Biologics LLC (US) | 2026-05-13 | — | — | EP | claimed |
| EP-3570831-B1 | THERAPEUTIC USE OF BETA-LACTAMS IN HEMATOPOIESIS, IMMUNO-ONCOLOGY THERAPY, AND REGULATION OF LIPOPROTEIN AND APOLIPOPROTEIN LEVELS | ALPHA 1 BIOLOGICS LLC (US) | 2026-03-25 | — | — | EP | claimed |
| CN-119082031-A | Method for inducing satellite glial cells to reversely differentiate into neural stem cell-like cells and application | 昆明医科大学 | 2024-12-06 | — | — | CN | claimed |
| US-12097190-B2 | Therapeutic use of levorotatory β-lactams in hematopoiesis, immuno-oncology therapy, and regulation of lipoprotein and apolipoprotein levels | ALPHA-1 BIOLOGICS, LLC (US) | 2024-09-24 | — | — | US | claimed |
| CN-113728924-B | Bluehead culture medium combination and culture method | 内蒙古蒙草生态环境（集团）股份有限公司 | 2023-08-18 | — | — | CN | claimed |
| US-20220273626-A1 | THERAPEUTIC USE OF LEVOROTATORY BETA-LACTAMS IN HEMATOPOIESIS, IMMUNO-ONCOLOGY THERAPY, AND REGULATION OF LIPOPROTEIN AND APOLIPOPROTEIN LEVELS | ALPHA-1 BIOLOGICS, LLC | 2022-09-01 | — | — | US | claimed |
| US-11324730-B2 | Therapeutic use of levorotatory β-lactams in hematopoiesis, immuno-oncology therapy, and regulation of lipoprotein and apolipoprotein levels | ALPHA-1 BIOLOGICS, LLC (US) | 2022-05-10 | — | — | US | claimed |
| EP-4747371-A1 | CHEMOGENETIC SURFACE MODIFIED VIRAL PARTICLES | Borea Therapeutics S.r.l. (IT) | 2026-05-27 | — | — | EP | disclosed |
| CN-122070366-A | Cyclic RNA compositions and methods | 欧纳医疗公司 | 2026-05-19 | — | — | CN | disclosed |
| EP-4740959-A2 | THERAPEUTIC USE OF LEVOROTATORY -LACTAMS IN HEMATOPOIESIS, IMMUNO-ONCOLOGY THERAPY, AND REGULATION OF LIPOPROTEIN AND APOLIPOPROTEIN LEVELS | Alpha-1 Biologics LLC (US) | 2026-05-13 | — | — | EP | disclosed |
| EP-3570831-B1 | THERAPEUTIC USE OF BETA-LACTAMS IN HEMATOPOIESIS, IMMUNO-ONCOLOGY THERAPY, AND REGULATION OF LIPOPROTEIN AND APOLIPOPROTEIN LEVELS | ALPHA 1 BIOLOGICS LLC (US) | 2026-03-25 | — | — | EP | disclosed |
| EP-3570831-B1 | THERAPEUTIC USE OF BETA-LACTAMS IN HEMATOPOIESIS, IMMUNO-ONCOLOGY THERAPY, AND REGULATION OF LIPOPROTEIN AND APOLIPOPROTEIN LEVELS | ALPHA 1 BIOLOGICS LLC (US) | 2026-03-25 | — | — | EP | disclosed |
| EP-4544037-B1 | CRISPR-CAS9-BASED LINEARIZATION OF PLASMID DNA TEMPLATES | WACKER CHEMIE AG (DE) | 2026-01-21 | — | — | EP | disclosed |
| US-10413530-B2 | Pharmaceutical composition containing the tromethamine salt of L-ampicillin | ALPHA-1 BIOLOGICS, LLC (US) | 2019-09-17 | — | — | US | disclosed |
| EP-3498717-A1 | COMPOSITION FOR HARDENING SOFT TISSUE | The Catholic University of Korea Industry-Academic Cooperation Foundation (KR) | 2019-06-19 | — | — | EP | disclosed |
| US-20180221349-A1 | THERAPEUTIC USE OF LEVOROTATORY SS-LACTAMS IN HEMATOPOIESIS, IMMUNO-ONCOLOGY THERAPY, AND REGULATION OF LIPOPROTEIN AND APOLIPOPROTEIN LEVELS | ALPHA-1 BIOLOGICS, LLC | 2018-08-09 | — | — | US | disclosed |
| US-20180221349-A1 | THERAPEUTIC USE OF LEVOROTATORY SS-LACTAMS IN HEMATOPOIESIS, IMMUNO-ONCOLOGY THERAPY, AND REGULATION OF LIPOPROTEIN AND APOLIPOPROTEIN LEVELS | ALPHA-1 BIOLOGICS, LLC | 2018-08-09 | — | — | US | disclosed |
| US-4115566-A | 7α Ureido cephem-4-carboxylic acid derivatives | CIBA-GEIGY CORPORATION (US) | 1978-09-19 | — | — | US | disclosed |
| US-3996208-A | PENICILLINS | CIBA-GEIGY CORPORATION (US) | 1976-12-07 | — | — | US | disclosed |
| US-3954802-A | Substituted-ureido derivatives of penam 3-carboxylic acid and cephem 4-carboxylic acid | CIBA-GEIGY CORPORATION (US) | 1976-05-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180221349-A1 | THERAPEUTIC USE OF LEVOROTATORY SS-LACTAMS IN HEMATOPOIESIS, IMMUNO-ONCOLOGY THERAPY, AND REGULATION OF LIPOPROTEIN AND APOLIPOPROTEIN LEVELS | CD4, APOL1, APOB | KDM4E 3413/4885RECQL 943/4885HPGD 2141/4885 |
| US-10413530-B2 | Pharmaceutical composition containing the tromethamine salt of L-ampicillin | CD4, IL2, TMSB10 | KDM4E 4611/4885RECQL 3410/4885HPGD 856/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.